These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8513454)

  • 1. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
    Siesjö P; Visse E; Lindvall M; Salford L; Sjögren HO
    Cancer Immunol Immunother; 1993 Jul; 37(1):67-74. PubMed ID: 8513454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased proportion of CD8+ tumor responsive T cells after immunization with tum- versus tum+ rat glioma.
    Siesjö P; Visse E; Sjögren HO
    Cell Immunol; 1995 Oct; 165(2):225-33. PubMed ID: 7553887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.
    Siesjö P; Visse E; Sjögren HO
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):334-45. PubMed ID: 8941873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells.
    Visse E; Siesjö P; Widegren B; Sjögren HO
    Cancer Gene Ther; 1999; 6(1):37-44. PubMed ID: 10078962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of glioma-infiltrating leucocytes after peripheral therapeutic immunization with interferon-gamma-transfected glioma cells.
    Visse E; Johansson AC; Widegren B; Sjögren HO; Siesjö P
    Cancer Immunol Immunother; 2000 Jun; 49(3):142-51. PubMed ID: 10881693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
    Badn W; Hegardt P; Fellert MA; Darabi A; Esbjörnsson M; Smith KE; Janelidze S; Salford LG; Visse E; Siesjö P
    Scand J Immunol; 2007 Mar; 65(3):289-97. PubMed ID: 17309784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
    Elliott BE; Carlow DA; Ivimey L; Arnold M; Hampton N; Bosman P
    Cancer Res; 1987 Sep; 47(18):4915-23. PubMed ID: 2441856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.
    Persson BR; Koch CB; Grafström G; Ceberg C; Munckaf Rosenschöld P; Nittby H; Widegren B; Salford LG
    Radiat Res; 2010 Apr; 173(4):433-40. PubMed ID: 20334515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models.
    Fritzell S; Eberstål S; Sandén E; Visse E; Darabi A; Siesjö P
    J Neuroimmunol; 2013 May; 258(1-2):91-5. PubMed ID: 23528658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors.
    Badn W; Visse E; Darabi A; Smith KE; Salford LG; Siesjö P
    J Immunol; 2007 Sep; 179(6):4231-8. PubMed ID: 17785863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for evaluating therapeutic response of combined cancer treatment modalities: applied to treatment of subcutaneously implanted brain tumors (N32 and N29) in Fischer rats with pulsed electric fields (PEF) and 60Co-gamma radiation (RT).
    Persson BR; Bauréus Koch C; Grafstrom G; Engstrom PE; Salford LG
    Technol Cancer Res Treat; 2003 Oct; 2(5):459-70. PubMed ID: 14529312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
    Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified immunoregulation associated with interferon-gamma treatment of rat glioma.
    Oshiro S; Liu Y; Fukushima T; Asotra K; Black KL
    Neurol Res; 2001 Jun; 23(4):359-66. PubMed ID: 11428516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N'-nitronitrosoguanidine.
    Gorelik E; Peppoloni S; Overton R; Herberman RB
    Cancer Res; 1985 Nov; 45(11 Pt 1):5341-7. PubMed ID: 2413992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy.
    Wen PY; Lampson MA; Lampson LA
    J Neuroimmunol; 1992 Jan; 36(1):57-68. PubMed ID: 1735769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
    Schartner JM; Hagar AR; Van Handel M; Zhang L; Nadkarni N; Badie B
    Glia; 2005 Sep; 51(4):279-85. PubMed ID: 15818597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.
    Akbasak A; Oldfield EH; Saris SC
    J Neurosurg; 1991 Dec; 75(6):922-9. PubMed ID: 1941122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
    Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
    Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment.
    Sainouchi R; Terata N; Kodama M
    Jpn J Cancer Res; 1988 Nov; 79(11):1247-53. PubMed ID: 3147279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.
    Uyttenhove C; Van Snick J; Boon T
    J Exp Med; 1980 Nov; 152(5):1175-83. PubMed ID: 6776226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.